Close Menu

financial guidance

The company also said that it expects to report fiscal 2015 revenues and EPS at the low end of its previously stated guidance range.

The Danish firm's research business grew 24 percent and its North American revenues grew 52 percent.

The firm's revenues were hit by currency translation and differences in the timing of test reimbursement compared with the previous year's quarter.

The company provided preliminary 2015 revenue guidance of $175 million to $190 million.

The company's chairman and CEO said that PositiveID has a sizeable backlog and pipeline of revenue opportunities for 2015. 

During its second quarter earnings call, Myriad officials detailed the market prospects for its tumor and germline BRACAnalysic CDx tests.

The preliminary revenues are on par with the average analyst estimate of $33.3.

The company initiated guidance for 2015 at a range of $4.35 to $4.45 per share.


NEW YORK (GenomeWeb) – Meridian Bioscience today released its revenue and earnings per share guidance for fiscal year 2015, coming in below Wall Street expectations.

NEW YORK (GenomeWeb) – Before the US Food and Drug Administration's draft guidance on laboratory-developed tests (LDTs) can be finalized, the agency will need to iron out with industry players several areas of regulation that remain unclear and confront old issues around the agency's authority ov


The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.